![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Z Abdel-Razzak, P Loyer, A Fautrel, JC Gautier, L Corcos, B Turlin, P Beaune and A Guillouzo
INSERM U 49, Hopital de Pontchaillou, Rennes, France.
Cytokines are thought to cause the depression of cytochrome P-450 (CYP)- associated drug metabolism in humans during inflammation and infection. We have examined the role of five cytokines, i.e., interleukin-1 beta, interleukin-4, interleukin-6, tumor necrosis factor-alpha, and interferon-gamma, on the expression of CYP1A2, CYP2C, CYP2E1, CYP3A, and epoxide hydrolase in primary human hepatocyte cultures. Steady state P-450 and epoxide hydrolase mRNA levels, as well as ethoxyresorufin-O-deethylase and nifedipine oxidation activities, which are mainly supported by CYP1A1/1A2 and CYP3A, respectively, were measured. Interleukin-1 beta, interleukin-6, and tumor necrosis factor- alpha were found to be the most potent depressors of P-450 enzymes. After 3 days of treatment, both mRNA levels and enzyme activities were depressed, typically by at least 40%, whatever the cytokine and the enzyme considered. Interferon-gamma also suppressed CYP1A2 and CYP2E1 mRNA levels and ethoxyresorufin-O-deethylase activity but had no effect on CYP3A and epoxide hydrolase mRNAs. In addition, interleukin-4 had the opposite effect, compared with other cytokines, on CYP2E1 mRNA, which was increased up to 5-fold; ethoxyresorufin-O-deethylase and nifedipine oxidation activities were not significantly affected. These results provide the first demonstration that various cytokines act directly on human hepatocytes to affect expression of major P-450 genes and that a wide range of responses can be observed among the enzymes for a given cytokine, suggesting that different regulatory mechanisms may be involved.
This article has been cited by other articles:
|
|
 |
|
  K. Nakai, H. Tanaka, K. Hanada, H. Ogata, F. Suzuki, H. Kumada, A. Miyajima, S. Ishida, M. Sunouchi, W. Habano, et al. Decreased Expression of Cytochromes P450 1A2, 2E1, and 3A4 and Drug Transporters Na+-Taurocholate-Cotransporting Polypeptide, Organic Cation Transporter 1, and Organic Anion-Transporting Peptide-C Correlates with the Progression of Liver Fibrosis in Chronic Hepatitis C Patients Drug Metab. Dispos., September 1, 2008; 36(9): 1786 - 1793. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Morey, J. C. Ryan, M.-Y. Bottein Dechraoui, A. H. Rezvani, E. D. Levin, C. J. Gordon, J. S. Ramsdell, and F. M. Van Dolah Liver Genomic Responses to Ciguatoxin: Evidence for Activation of Phase I and Phase II Detoxification Pathways following an Acute Hypothermic Response in Mice Toxicol. Sci., June 1, 2008; 103(2): 298 - 310. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-M. Huang, J. M. Strong, L. Zhang, K. S. Reynolds, S. Nallani, R. Temple, S. Abraham, S. A. Habet, R. K. Baweja, G. J. Burckart, et al. New Era in Drug Interaction Evaluation: US Food and Drug Administration Update on CYP Enzymes, Transporters, and the Guidance Process J. Clin. Pharmacol., June 1, 2008; 48(6): 662 - 670. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Le Vee, P. Gripon, B. Stieger, and O. Fardel Down-Regulation of Organic Anion Transporter Expression in Human Hepatocytes Exposed to the Proinflammatory Cytokine Interleukin 1{beta} Drug Metab. Dispos., February 1, 2008; 36(2): 217 - 222. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Mahmood and M. D. Green Drug Interaction Studies of Therapeutic Proteins or Monoclonal Antibodies J. Clin. Pharmacol., December 1, 2007; 47(12): 1540 - 1554. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Liu, H. Sun, W. Y. Valji, and K. S. Pang Transporters, enzymes, and enalapril removal in a rat (CC531-induced) liver metastatic model Am J Physiol Gastrointest Liver Physiol, November 1, 2007; 293(5): G1078 - G1088. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. E. Aitken and E. T. Morgan Gene-Specific Effects of Inflammatory Cytokines on Cytochrome P450 2C, 2B6 and 3A4 mRNA Levels in Human Hepatocytes Drug Metab. Dispos., September 1, 2007; 35(9): 1687 - 1693. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Q. Pham and A. Q. Pham Interaction potential between cranberry juice and warfarin Am. J. Health Syst. Pharm., March 1, 2007; 64(5): 490 - 494. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Naud, J. Michaud, C. Boisvert, K. Desbiens, F. A. Leblond, A. Mitchell, C. Jones, A. Bonnardeaux, and V. Pichette Down-Regulation of Intestinal Drug Transporters in Chronic Renal Failure in Rats J. Pharmacol. Exp. Ther., March 1, 2007; 320(3): 978 - 985. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Michaud, J. Naud, J. Chouinard, F. Desy, F. A. Leblond, K. Desbiens, A. Bonnardeaux, and V. Pichette Role of Parathyroid Hormone in the Downregulation of Liver Cytochrome P450 in Chronic Renal Failure J. Am. Soc. Nephrol., November 1, 2006; 17(11): 3041 - 3048. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. T. Donato, A. Lahoz, N. Jimenez, G. Perez, A. Serralta, J. Mir, J. V. Castell, and M. J. Gomez-Lechon Potential Impact of Steatosis on Cytochrome P450 Enzymes of Human Hepatocytes Isolated from Fatty Liver Grafts Drug Metab. Dispos., September 1, 2006; 34(9): 1556 - 1562. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Aninat, A. Piton, D. Glaise, T. Le Charpentier, S. Langouet, F. Morel, C. Guguen-Guillouzo, and A. Guillouzo EXPRESSION OF CYTOCHROMES P450, CONJUGATING ENZYMES AND NUCLEAR RECEPTORS IN HUMAN HEPATOMA HepaRG CELLS Drug Metab. Dispos., January 1, 2006; 34(1): 75 - 83. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. White, B. L. Calver, V. Newsway, R. Wade, S. Patel, A. Bayer, and M. S. O'Mahony Enzymes of drug metabolism during delirium Age Ageing, November 1, 2005; 34(6): 603 - 608. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Tochigi, N. Yamashiki, S. Ohgiya, S. Ganaha, and H. Yokota ISOFORM-SPECIFIC EXPRESSION AND INDUCTION OF UDP-GLUCURONOSYLTRANSFERASE IN IMMUNOACTIVATED PERITONEAL MACROPHAGES OF THE RAT Drug Metab. Dispos., September 1, 2005; 33(9): 1391 - 1398. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Liu, R. F. Frye, R. A. Branch, R. Venkataramanan, J. J. Fung, and G. J. Burckart Effect of Age and Postoperative Time on Cytochrome P450 Enzyme Activity Following Liver Transplantation J. Clin. Pharmacol., June 1, 2005; 45(6): 666 - 673. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Tian, J. Ou, S. C. Strom, and R. Venkataramanan PHARMACOKINETICS OF TACROLIMUS AND MYCOPHENOLIC ACID ARE ALTERED, BUT RECOVER AT DIFFERENT TIMES DURING HEPATIC REGENERATION IN RATS Drug Metab. Dispos., March 1, 2005; 33(3): 329 - 335. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Kelicen and N. Tindberg Lipopolysaccharide Induces CYP2E1 in Astrocytes through MAP Kinase Kinase-3 and C/EBP{beta} and -{delta} J. Biol. Chem., April 16, 2004; 279(16): 15734 - 15742. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Sunman, R. L. Hawke, E. L. LeCluyse, and A. D. M. Kashuba KUPFFER CELL-MEDIATED IL-2 SUPPRESSION OF CYP3A ACTIVITY IN HUMAN HEPATOCYTES Drug Metab. Dispos., March 1, 2004; 32(3): 359 - 363. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kawaguchi, Y. Matsui, Y. Watanabe, and Y. Takakura Effect of Interferon-{gamma} on the Pharmacokinetics of Digoxin, a P-glycoprotein Substrate, Intravenously Injected into the Mouse J. Pharmacol. Exp. Ther., January 1, 2004; 308(1): 91 - 96. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. O. Qiu, M. W. Linder, D. M. Antonino-Green, and R. Valdes Jr. Suppression of Cytochrome P450 2E1 Promoter Activity by Interferon-{gamma} and Loss of Response Due to the -71G>T Nucleotide Polymorphism of the CYP2E1*7B Allele J. Pharmacol. Exp. Ther., January 1, 2004; 308(1): 284 - 288. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Hayney and D. Muller Effect of Influenza Immunization on CYP3A4 Activity In Vivo J. Clin. Pharmacol., December 1, 2003; 43(12): 1377 - 1381. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-J. Lin, P.-Y. Shu, C. Chang, A.-K. Ng, and C.-p. Hu IL-4 Suppresses the Expression and the Replication of Hepatitis B Virus in the Hepatocellular Carcinoma Cell Line Hep3B J. Immunol., November 1, 2003; 171(9): 4708 - 4716. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Salonen, L. Nyman, A. R. Boobis, R. J. Edwards, P. Watts, B. G. Lake, R. J. Price, A. B. Renwick, M.-J. Gomez-Lechon, J. V. Castell, et al. COMPARATIVE STUDIES ON THE CYTOCHROME P450-ASSOCIATED METABOLISM AND INTERACTION POTENTIAL OF SELEGILINE BETWEEN HUMAN LIVER-DERIVED IN VITRO SYSTEMS Drug Metab. Dispos., September 1, 2003; 31(9): 1093 - 1102. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Hakkola, Y. Hu, and M. Ingelman-Sundberg Mechanisms of Down-Regulation of CYP2E1 Expression by Inflammatory Cytokines in Rat Hepatoma Cells J. Pharmacol. Exp. Ther., March 1, 2003; 304(3): 1048 - 1054. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ke, A. B. Rabson, J. F. Germino, M. A. Gallo, and Y. Tian Mechanism of Suppression of Cytochrome P-450 1A1 Expression by Tumor Necrosis Factor-alpha and Lipopolysaccharide J. Biol. Chem., October 19, 2001; 276(43): 39638 - 39644. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.-M. Bleau, C. Fradette, A. O. S. El-Kadi, M.-C. Cote, and P. du Souich Cytochrome P450 Down-Regulation by Serum from Humans with a Viral Infection and from Rabbits with an Inflammatory Reaction Drug Metab. Dispos., July 1, 2001; 29(7): 1007 - 1012. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. B. Andersson, H. Sjöberg, K.-J. Hoffmann, A. R. Boobis, P. Watts, R. J. Edwards, B. G. Lake, R. J. Price, A. B. Renwick, M. J. Gómez-Lechón, et al. An Assessment of Human Liver-Derived in Vitro Systems to Predict the in Vivo Metabolism and Clearance of Almokalant Drug Metab. Dispos., April 13, 2001; 29(5): 712 - 720. [Abstract] [Full Text]
|
|
|
|
|
|
E. T. Morgan Regulation of Cytochrome P450 by Inflammatory Mediators: Why and How? Drug Metab. Dispos., March 1, 2001; 29(3): 207 - 212. [Abstract] [Full Text]
|
|
|
|
|
|
J. Pan, Q. Xiang, and S. Ball Use of a Novel Real-Time Quantitative Reverse Transcription-Polymerase Chain Reaction Method to Study the Effects of Cytokines on Cytochrome P450 mRNA Expression in Mouse Liver Drug Metab. Dispos., June 1, 2000; 28(6): 709 - 713. [Abstract] [Full Text]
|
|
|
|
 |
|
 Y. Morel, I. de Waziers, and R. Barouki A Repressive Cross-Regulation between Catalytic and Promoter Activities of the CYP1A1 and CYP2E1 Genes: Role of H2O2 Mol. Pharmacol., June 1, 2000; 57(6): 1158 - 1164. [Abstract] [Full Text]
|
|
|
|
|
|
E. G. Schuetz, D. R. Umbenhauer, K. Yasuda, C. Brimer, L. Nguyen, M. V. Relling, J. D. Schuetz, and A. H. Schinkel Altered Expression of Hepatic Cytochromes P-450 in Mice Deficient in One or More mdr1 Genes Mol. Pharmacol., January 1, 2000; 57(1): 188 - 197. [Abstract] [Full Text]
|
|
|
|
 |
|
 C. M. Pastor and P. M. Suter Hepatic Hemodynamics and Cell Functions in Human and Experimental Sepsis Anesth. Analg., August 1, 1999; 89(2): 344 - 344. [Full Text] [PDF]
|
|
|
|
|
|
M. Tinel, J. Elkahwaji, M. A. Robin, N. Fardel, V. Descatoire, D. Haouzi, A. Berson, and D. Pessayre Interleukin-2 Overexpresses c-myc and Down-Regulates Cytochrome P-450 in Rat Hepatocytes J. Pharmacol. Exp. Ther., May 1, 1999; 289(2): 649 - 655. [Abstract] [Full Text]
|
|
|
|
|
|
A. Simi and M. Ingelman-Sundberg Post-Translational Inhibition of Cytochrome P-450 2E1 Expression by Chlomethiazole in Fao Hepatoma Cells J. Pharmacol. Exp. Ther., May 1, 1999; 289(2): 847 - 852. [Abstract] [Full Text]
|
|
|
|
|
|
Y. Tian, S. Ke, Michael. S. Denison, A. B. Rabson, and M. A. Gallo Ah Receptor and NF-kappa B Interactions, a Potential Mechanism for Dioxin Toxicity J. Biol. Chem., January 1, 1999; 274(1): 510 - 515. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. B. Sewer and E. T. Morgan Down-Regulation of the Expression of Three Major Rat Liver Cytochrome P450S by Endotoxin In Vivo Occurs Independently of Nitric Oxide Production J. Pharmacol. Exp. Ther., October 1, 1998; 287(1): 352 - 358. [Abstract] [Full Text]
|
|
|
|
 |
|
 E. Levesque, M. Beaulieu, C. Guillemette, D. W. Hum, and A. Belanger Effect of Interleukins on UGT2B15 and UGT2B17 Steroid Uridine Diphosphate-Glucuronosyltransferase Expression and Activity in the LNCaP Cell Line Endocrinology, May 1, 1998; 139(5): 2375 - 2381. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. I. Guillén, M. T. Donato, R. Jover, J. V. Castell, R. Fabra, R. Trullenque, and M. J. Gómez-Lechón Oncostatin M Down-regulates Basal and Induced Cytochromes P450 in Human Hepatocytes J. Pharmacol. Exp. Ther., April 1, 1998; 285(1): 127 - 134. [Abstract] [Full Text]
|
|
|
|
|
|
K. Maheo, J. Antras-Ferry, F. Morel, S. Langouet, and A. Guillouzo Modulation of Glutathione S-Transferase Subunits A2, M1, and P1 Expression by Interleukin-1beta in Rat Hepatocytes in Primary Culture J. Biol. Chem., June 27, 1997; 272(26): 16125 - 16132. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Döhr, R. Sinning, C. Vogel, P. Münzel, and J. Abel Effect of Transforming Growth Factor-beta 1 on Expression of Aryl Hydrocarbon Receptor and Genes of Ah Gene Battery: Clues for Independent Down-Regulation in A549 Cells Mol. Pharmacol., May 1, 1997; 51(5): 703 - 710. [Abstract] [Full Text]
|
|
|
|
|
|
M. T. Donato, M. I. Guillén, R. Jover, J. V. Castell, and M. J. Gómez-Lechón Nitric Oxide-Mediated Inhibition of Cytochrome P450 by Interferon-gamma in Human Hepatocytes J. Pharmacol. Exp. Ther., April 1, 1997; 281(1): 484 - 490. [Abstract] [Full Text]
|
|
|
|
|
|
C. Y. Ng, H. Ghabrial, D. J. Morgan, R. A. Smallwood, and P. W. Angus Effects of Acute Myocardial Infarction on Theophylline Elimination in Rats Drug Metab. Dispos., January 1, 1997; 25(1): 61 - 65. [Abstract] [Full Text]
|
|
|
|
 |
|
 X. Fang, T. L. Kaduce, N. L. Weintraub, M. VanRollins, and A. A. Spector Functional Implications of a Newly Characterized Pathway of 11,12-Epoxyeicosatrienoic Acid Metabolism in Arterial Smooth Muscle Circ. Res., October 1, 1996; 79(4): 784 - 793. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
